The impact of comorbid disease history on all-cause and cancer-specific mortality in myeloid leukemia and myeloma - a Swedish population-based study.

Background

Survival from myeloid leukemia and myeloma has improved during recent decades, but still more than 150,000 patients died of these malignancies worldwide in 2012 [ 1 , 2 ]. The incidence of most hematological malignancies increases with age, as does the prevalence of many non-malignant chronic disorders [ 3 ]. Although patients with comorbid disease can be expected to have a lower tolerance to standard chemotherapy-based regimens used to treat hematological malignancies, evidence to guide clinical decision making in these situations is poor. Clinical trials used as a basis for general treatment recommendations provide insufficient guidance for the treatment of patients with severe comorbid disease since these patients are often underrepresented.

Among cancer patients in general, severe comorbid disease increases overall mortality [ 4 ], but results for cancer-specific mortality are mixed [ 5 – 8 ]. In hematological malignancies, multiple studies have established comorbid disease overall as an independent predictor of all-cause mortality [ 9 – 14 ], especially among patients eligible for hematopoietic stem cell transplantation [ 15 – 17 ]. However, most of these studies exclude patients over 70 years of age. Low socioeconomic status has been associated with elevated mortality among patients with acute myeloid leukemia (AML) and multiple myeloma [ 18 ], potentially mediated through a more advanced disease at the time of diagnosis, and/or through comorbid disease. Another potential mediating factor between low SES and mortality is access to health care services, although the Swedish social security system does offer universal access of care.

For most hematological malignancies, it is not clear to what extent specific comorbid diseases affect overall and cancer-specific survival, and if effects differ by age. Such estimations could guide clinicians in choosing the most optimal treatments for these patients. E.g., if comorbid disease would be associated with overall survival through other-cause death rather than cancer-specific death, a wait and watch strategy or low-intensity treatment may be the best options. In this nationwide population-based register study, we examined the impact of severe comorbid disease history (according to the Charlson comorbidity index [ 19 ] and later modification [ 20 ]) on survival among patients diagnosed with myeloid leukemia or myeloma in Sweden 2002 to 2009. We also aimed to investigate potential variation in the effect of comorbidities on survival by type of comorbid disease, type of hematological malignancy and age.

Methods

In a prospective register-based cohort study, we identified all individuals aged > 18 years, diagnosed with a first incident AML, chronic myeloid leukemia (CML) or myeloma from 2002 to 2009 in the Swedish Cancer Register (coverage > 95 % [ 21 , 22 ]) using the International Classification of Diseases (ICD), 10 th revision (Additional file 1 , Table S1). Patients diagnosed at autopsy or with a history of stem cell or solid organ transplantation prior to the leukemia/myeloma diagnosis ( n = 47) were excluded. The study was approved by the Regional Ethical Committee in Stockholm, Sweden (2010/1624–32). Since we used de-identified register data, individual informed consent was not sought in line with institutional regulations.

Comorbid disease

The cohort was linked to the Swedish Patient Register including in- and outpatient data (coverage 85–95 % [ 23 ]) to collect dates of hospital visits and admissions, and main and secondary diagnoses of comorbid disease listed in the modified Charlson index [ 19 , 20 ] with the addition of psychiatric disorders (Additional file 1 : Table S1), during a period of 5 years prior to the diagnosis of leukemia/myeloma. Records of rheumatologic and renal diseases were disregarded if they occurred during the year leading up to the diagnosis of leukemia/ myeloma since their occurrence could be a sign of the yet undiagnosed malignancy. Rheumatologic disorders only recorded closely in time to a diagnosis of a hematological malignancy may represent misclassified paramalignant phenomena rather than true autoimmune/inflammatory disease [ 24 , 25 ]. Similarly, records of kidney dysfunction shortly before myeloma diagnosis could be a sign of myeloma rather than kidney disease [ 26 ]. Cancer history (excluding non-melanoma skin neoplasms) any time prior to the leukemia/myeloma was identified in the Swedish Cancer Register. Due to the possibility of misclassification between subtypes of hematological malignancies we excluded patients with prior history of any hematological malignancy from the study cohort. For patients with AML, we specifically noted a preceding diagnosis of myelodysplastic disorders (MDS) or myeloproliferative neoplasms (MPN).

Sociodemographic factors

Through the longitudinal integrated database for health insurance and labor market (LISA), we assembled information on educational level [ 27 ]. The highest achieved educational level (< 10 years/10–12 years/ > 12 years) before diagnosis of leukemia/myeloma was used as a proxy for socioeconomic status [ 28 , 29 ].

Outcome

Patients were followed from the date of diagnosis of leukemia/myeloma until emigration, death or December 31st 2012, whichever occurred first. Dates and causes of death were obtained from the Cause-of-Death register (coverage > 99 % [ 30 ]). Death records with ICD10 codes for leukemia/myeloma as the main underlying cause of death were treated as cancer-specific death, otherwise as other-cause death (Additional file 1 : Table S1). Leukemia- myeloma-specific death was defined along the lines proposed by Howlader et. al. [ 31 ] including a group of related codes for cancer-specific death. In validation studies, the information on main cause of death collected from Swedish Cause of Death Register for malignant neoplasms has been highly accurate [ 30 , 32 ].

Statistical methods

The associations of comorbid disease history and specific comorbidities with all-cause, cancer-specific and other-cause death were estimated as mortality rate ratios (MRR) with 95 % confidence intervals (CI) using Poisson regression. When estimating the effect of specific comorbid diseases on survival, all patients without the investigated type were included in the reference group. All analyses were adjusted for follow-up time (1-year intervals), age at diagnosis (10-year intervals), sex, calendar year of diagnosis, country of birth and education level. When assessing the statistical significance of interaction terms between comorbidity and time since diagnosis, we found no evidence of non-proportional hazards ( p < 0.05). Moreover, for patients aged 60–89 years at diagnosis, the probability of cancer-specific and other-cause death was estimated in the presence of competing risks, using estimates from flexible parametric survival models [ 33 ]. These models use restricted cubic splines to model the baseline cause-specific hazard rates. The fitted models were stratified by age and sex, and used 3°-of-freedom to model the baseline hazard functions. All statistical analyses were performed with STATA software version 13 (StataCorp. 2013. College Station, TX: StataCorp LP).

Results

We identified 2,550 patients with AML, 1,000 with CML and 4,584 with myeloma diagnosed in Sweden between 2002 and 2009 (Table 1 ). Median age at diagnosis was 72 years in AML and myeloma, and 67 years in CML. Median follow-up in AML was 0.6 (range 0–11) years, in CML 4.2 (range 0–11) years, and in myeloma 3.1 (range 0–11) years. Approximately 40 % of the patients had a history of comorbid disease (AML: 43 %; CML: 35 %; myeloma: 38 %) (Table 1 ). As expected, the prevalence of comorbidity increased with age and among patients diagnosed at 80+ years, more than half had a history of comorbidity (AML and CML: 59 %, myeloma 52 %). Non-hematological cancers (13–15 %) and cardiovascular disease (10–14 %) were the most common comorbid disease groups (Table 1 ). Table 1 Characteristics of patients with AML, CML and myeloma, Sweden 2002–2009, and proportion with comorbid disease AML a CML b Myeloma All CD c All CD c All CD c No (%) No (%) No (%) No (%) No (%) No (%) Total 2550 (100) 1105 (43) 1000 (100) 350 (35) 4584 (100) 1735 (38) Median follow up (year) 0.6 (0.0–11) 4.2 (0.0–11) 3.1 (0.0–11) Sex Women 1262 (50) 532 (42) 446 (45) 155 (35) 2075 (45) 745 (36) Men 1288 (50) 573 (44) 554 (55) 195 (35) 2509 (55) 990 (39) Age 18–49 336 (13) 50 (15) 210 (21) 19 (9) 219 (4.8) 32 (15) 50–59 307 (12) 82 (27) 147 (15) 26 (18) 605 (13) 121 (20) 60–69 505 (20) 204 (40) 208 (21) 72 (35) 1145 (25) 349 (30) 70–79 746 (29) 382 (51) 242 (24) 120 (50) 1499 (33) 651 (43) 80+ 656 (26) 387 (59) 193 (19) 113 (59) 1116 (24) 582 (52) Median age (range) 72 (18–100) 67 (18–99) 72 (24–97) Country of birth Sweden 2279 (89) 996 (44) 881 (88) 313 (36) 4088 (89) 1553 (38) Outside of Sweden 271 (11) 109 (40) 119 (12) 37 (31) 496 (11) 182 (37) Education level 0–9 years 1065 (42) 533 (50) 376 (38) 163 (43) 1997 (44) 888 (44) 10–12 years 958 (38) 383 (40) 400 (40) 122 (31) 1612 (35) 557 (35) > 12 years 464 (18) 157 (34) 204 (20) 57 (28) 897 (20) 264 (29) Missing 63 (2.5) 32 (51) 20 (2.0) 8 (40) 78 (1.7) 26 (33) No. of comorbid diseases 0 1445(57) 650 (65) 2849 (62) 1 732 (29) 225 (22) 1154 (25) 2+ 373 (15) 125 (12) 581 (13) Types of comorbid diseases Cancer 372 (15) 134 (13) 601 (13) Cardiovascular disease 355 (14) 105 (10) 510 (11) Diabetes 235 (9.2) 72 (7.2) 377 (8.2) Cerebrovascular disease 200 (7.8) 54 (5.4) 262 (5.7) Chronic pulmonary disease 148 (5.8) 51 (5.1) 243 (5.3) Peripheral vascular disease 77 (3.0) 30 (3.0) 97 (2.1) Peptic ulcer disease 51 (2.0) 30 (3.0) 110 (2.4) Rheumatologic disease 82 (3.2) 20 (2.0) 71 (1.5) Renal disease 22 (0.9) 5 (0.5) 55 (1.2) Liver disease 20 (0.8) 8 (0.8) 44 (1.0) Dementia 25 (1.0) 10 (1.0) 49 (1.1) Psychiatric disorders 29 (1.1) 16 (1.6) 73 (1.6) Hemiplegia/Paraplegia 5 (0.2) 3 (0.3) 31 (0.7) AIDS/HIV 0 (0.0) 0 (0.0) 2 (0.04) a AML acute myeloid leukemia, b CML chronic myeloid leukemia, c CD comorbid disease

Most deaths were classified as cancer-specific, especially in AML (Additional file 2 : Table S2). In general, patients with a history of any of the specified comorbid diseases had an increased rate of all-cause death compared with patients without such history (Table 2 ). The relative rate of other-cause death was higher than that of cancer-specific death, although cancer-specific death was also significantly increased among patients with comorbid disease history compared to those without in AML and myeloma, and borderline significantly increased among CML patients. In addition, female sex and higher attained education level tended to be associated with a more favorable prognosis (Table 2 ). Adjustment for age in 5-year instead of 10-year intervals did not change the results. Table 2 MRR a for all-cause, cancer-specific and other-cause death among AML CML and myeloma patients, Sweden 2002–2009 AML b MRR (95 % CI) CML c MRR (95 % CI) Myeloma MRR (95 % CI) All-cause death Comorbid disease No 1.00 1.00 1.00 Yes 1.39 (1.26–1.52) 1.64 (1.34–2.01) 1.40 (1.30–1.50) No. of comorbid diseases 0 1.00 1.00 1.00 1 1.25 (1.12–1.38) 1.41 (1.12–1.77) 1.29 (1.19–1.40) 2+ 1.78 (1.57–2.02) 2.22 (1.71–2.88) 1.67 (1.51–1.85) Sex Men 1.00 1.00 1.00 Women 0.91 (0.84–1.00) 0.83 (0.69–1.02) 0.89 (0.83–0.95) Education level 0–9 1.00 1.00 1.00 10–12 0.98 (0.89–1.09) 1.09 (0.89–1.35) 0.97 (0.89–1.04) > 12 0.80 (0.70–0.91) 0.93 (0.70–1.25) 0.83 (0.75–0.92) Cancer-specific death Comorbid disease No 1.00 1.00 1.00 Yes 1.27 (1.15–1.40) 1.28 (0.96–1.70) 1.17 (1.08–1.28) No. of comorbid diseases 0 1.00 1.00 1.00 1 1.16 (1.04–1.29) 1.12 (0.81–1.55) 1.12 (1.02–1.23) 2+ 1.60 (1.39–1.83) 1.66 (1.13–2.44) 1.31 (1.15–1.48) Sex Men 1.00 1.00 1.00 Women 0.92 (0.84–1.01) 0.91 (0.70–1.20) 0.91 (0.84–0.99) Education level 0–9 1.00 1.00 1.00 10–12 0.97 (0.87–1.08) 1.19 (0.89–1.58) 0.96 (0.88–1.06) > 12 0.80 (0.69–0.91) 0.72 (0.46–1.12) 0.87 (0.78–0.97) Other-cause death Comorbid disease No 1.00 1.00 1.00 Yes 2.64 (2.00–3.48) 2.14 (1.60–2.85) 2.22 (1.94–2.55) No. of comorbid diseases 0 1.00 1.00 1.00 1 2.22 (1.64–3.01) 1.80 (1.30–2.49) 1.91 (1.64–2.23) 2+ 3.86 (2.72–5.47) 2.98 (2.07–4.30) 3.02 (2.53–3.62) Sex Men 1.00 1.00 1.00 Women 0.90 (0.69–1.16) 0.76 (0.58–1.01) 0.82 (0.72–0.94) Education level 0–9 1.00 1.00 1.00 10–12 1.07 (0.79–1.43) 1.00 (0.73–1.36) 0.97 (0.83–1.13) > 12 0.85 (0.58–1.25) 1.17 (0.80–1.73) 0.72 (0.58–0.88) a MRR mortality rate ratios adjusted for age (in 10 year intervals), country of birth, time since diagnosis, calendar year of diagnosis and number of comorbid diseases, sex and education level except when main effects of these factors were estimated, statistically significant results (p<0.05) are in bold. b AML acute myeloid leukemia, c CML chronic myeloid leukemia

Acute myeloid leukemia (AML)

A higher all-cause as well as cancer-specific mortality in AML was observed for patients with previous cerebrovascular disease, rheumatologic diseases, renal disease, liver disease and psychiatric disease (Fig. 1 ). Dementia was also significantly associated with AML-specific mortality. Renal disorders were associated with the highest increase in mortality (MRR all-cause death = 3.10, 95 % CI: 1.96–4.89; MRR AML-specific death =2.46, 1.41–4.27, Fig. 1 ). Two-hundred and fourteen AML patients (8.3 %) had a prior record of MDS/MPN (MDS = 137, MPN = 77). Adjustment for previous MDS/MPN did not meaningfully alter the associations between non-hematological comorbidities and cancer-specific mortality. To address the relative contribution of prior cancer treatment, we also analyzed outcomes in association with non-malignant comorbidities separately, and results remained virtually unchanged. Fig. 1 MRR for all-cause and cancer-specific death by type of comorbid disease. MRR mortality rate ratios adjusted for age (in 10 year intervals), country of birth, time since diagnosis, calendar year of diagnosis and number of comorbid diseases, sex and education level except when main effects of these factors were estimated. AML acute myeloid leukemia, CML chronic myeloid leukemia, CPD , chronic pulmonary disease. * Because of few patients with hemiplegia/paraplegia ( n = 49) and HIV/AIDS ( n = 2) overall, and with liver disease in CML, results for these groups are not presented

In analyses of the absolute impact of comorbid disease history in the age groups 60–69, 70–79 and 80–89 years by sex, the probability of dying from AML was greater than the probability of dying from other causes in both sexes and in all investigated age groups, irrespective of the presence of comorbid disease (Fig. 2 , Additional file 3 : Table S3). The proportion of male patients aged 60–79 years who died from AML within the first 5 years after diagnosis was significantly higher for patients with at least one comorbid disease than for those without (ages 60–69: 76 % vs 65 %, difference 11 % (95 % CI 3.5–19); ages 70–79: 86 % vs 81 %, difference 4.8 % (95 % CI 1.5–7.9)) . Among patients 80–89 years, comorbid disease history was not associated with a higher cancer-specific probability of death (Fig. 2 ). For female patients aged 60–89 years, the pattern was similar, although in the oldest group, AML-specific deaths encompassed a larger share of all deaths as compared to males (Fig. 2 , Additional file 4 : Table S4). Fig. 2 Stacked cumulative probability of cancer-specific and other-cause death among AML patients aged 60–89 years

Chronic myeloid leukemia (CML)

In analyses of specific comorbid diseases, most tended to be associated with a nominally higher all-cause as well as CML-specific mortality, but numbers were low reducing the precision. History of cardiovascular and renal disorders and dementia were significantly associated with all-cause death, whereas only renal disorders were associated with increased risk of CML-specific death (MRR = 7.47, 95 % CI: 1.66–33.6) (Fig. 1 ). Among men 70–89 years of age (but not those aged 60–69 years), the probability of dying from causes other than CML was greater than the probability of dying from CML within 5 years after diagnosis, regardless of the presence or absence of comorbidity (Fig. 3 ). Among men 60–69 years, the 5-year probability of CML-specific death was significantly higher for those with comorbid disease than those without (31 vs 18 %, difference 12.6 %, 95 % CI: 2.5–22.7, Additional file 3 : Table S3). In older age groups there were no statistically significant differences in probabilities of cancer-specific or other-cause death among patients with and without comorbidities. In contrast, among women, comorbid disease conferred a higher probability of mainly cancer-specific death in ages 80–89 years (55 vs 41 %, difference 13.7, 95 % CI: 3.6–23.8) but no significant differences in cancer-specific or other-cause death in younger age groups (Additional file 4 : Table S4). Fig. 3 Stacked cumulative probability of cancer-specific and other-cause death, among CML patients aged 60–89 years

Myeloma

A history of cardiovascular, cerebrovascular, chronic pulmonary or renal disease, or dementia were associated with a higher all-cause as well as myeloma-specific mortality (Fig. 1 ). Liver and ulcer disease were additionally associated with all-cause mortality whereas psychiatric disease was associated with myeloma-specific mortality only. No one with renal disease had a complementary diagnosis code of amyloidosis.

All myeloma patient groups by sex and age (60–89 years) were more likely to die of myeloma than other causes (Fig. 4 ). Irrespective of age at diagnosis and sex, the 5-year probability of death from myeloma mainly, but also of other-cause death, was significantly higher among patients with comorbidities than among patients without (Additional file 3 : Table S3, Additional file 4 : Table S4). In absolute terms, the percentage differences in the probabilities of patients who died from myeloma within 5 years in the two groups with and without comorbidity were moderate, ranging from 5.8 to 10.9 (Fig. 4 ). Fig. 4 Stacked cumulative probability of cancer-specific and other-cause death, among myeloma patients aged 60–89 years

Discussion

In this large population-based study, using prospectively recorded information on comorbid diseases, we showed that patients with a history of comorbidity at diagnosis of AML, CML or myeloma had a higher all-cause but also cancer-specific mortality compared with patients without such history, reflecting an impact on disease-specific outcome in these malignancies. Renal disorders were associated with a markedly higher cancer-specific mortality among all three patient groups (but were uncommon, prevalence 0.5–1 %). Cerebrovascular disease, dementia and psychiatric disease were associated with an increased risk of cancer-specific death in AML and myeloma patients, liver and rheumatologic disease increased risk in AML only, and cardiovascular and chronic pulmonary disease in myeloma only. In absolute terms, the 5-year probability of cancer-specific death was greater than that of other-cause death among all patients aged 60–89 years except among male patients > 70 years with CML. Comorbidity contributed most to cancer-specific death among younger patients (< 70 years) in AML, whereas the impact was constant by age in myeloma.

AML

The achievement of complete remission and long-term survival in AML mostly requires intensive combination chemotherapy, and outcomes are strongly dependent upon age and performance status [ 34 , 35 ]. During the study period in Sweden, the majority of the patients diagnosed up to the age of 80 years received intense treatment [ 34 ]. Whether further prognostic stratification and personalized therapy can be achieved by adding a more systematic evaluation of comorbidity has been investigated in a few previous studies. In most [ 12 , 13 , 36 – 38 ], but not all [ 14 ] of these, comorbidity assessed using the Charlson index was independently associated with a worse overall survival. Etienne et al. ( N = 133) showed that comorbid diseases (with an index score > 1) negatively predicted complete remission rate [ 13 ]. In two recent large studies, a lower likelihood of treatment with intense chemotherapy was noted in the presence of comorbid disease [ 14 , 37 ]. In Ostgard et al. [ 14 ], comorbidity was not associated with survival when adjusted for performance status and other factors. Performance status could however be considered an intermediate explanatory factor rather than a true confounder and therefore an association between comorbidity and survival through lower performance status is still plausible. In that study, outcome was also investigated in relation to specific comorbid disease, and dementia, heart failure and renal failure were associated with opting-out of intensive therapy [ 14 ]. This is in line with our findings of a decreased cancer-specific survival in patients with renal disease and dementia. A similar explanation is plausible among patients with cerebrovascular and psychiatric disease, also noted to have a worse cancer-specific survival in our study.

Ostgard et al. also observed an indication of a stronger association between comorbidity and outcome among patients < 60 versus > 60 years of age. Extending these previous results, we show a clear differential effect of comorbidity by age with a larger prognostic importance of comorbidity among patients 60–69 years versus older patients. Hence, our results provide additional support for the notion that poor outcomes among AML patients > 70 years cannot be explained solely on the basis of increased prevalence of comorbidity by age but [ 14 , 34 ], rather through a more general low treatment tolerance at older ages.

CML

CML survival has improved greatly with the introduction of tyrosine kinase inhibitors such as imatinib (introduced in 2001 in Sweden) [ 39 ] although elderly Swedish CML patients (> 79 years) still have a 5-year relative survival of only 60 % [ 40 ], that may reflect under-implementation of tyrosine kinase inhibitor use [ 39 , 40 ]. A few previous studies have shown a negative impact of comorbidity on CML survival in line with our results, mainly reflected in a poorer event-free survival [ 36 ] or lower degree of complete cytogenic response [ 41 , 42 ]. Previous studies have assessed comorbidity through pooled indices including the Charlson comorbidity index [ 36 , 41 ], or the adult comorbidity evaluation-27 score and cumulative illness rating scale [ 36 , 41 ], but have not investigated survival by specific comorbidities, perhaps due to low numbers. We show for the first time that prior renal disease is associated with a poorer cancer-specific survival in CML. Renal disease is not an absolute contraindication for use of tyrosine kinase inhibitors, but glomerular filtration rate may decrease further during tyrosine kinase inhibitors treatment [ 43 ]. Thus, dose reductions [ 44 ] or caution to prescribe tyrosine kinase inhibitors could potentially explain this finding. Also, high comorbidity index has been associated with an increased risk of toxicity to tyrosine kinase inhibitors in two previous studies [ 41 , 45 ].

A previous cohort study indicated that treatment of elderly CML patients ( n = 181, median age 79 years) might be influenced by the individual physician’s perception and could be improved by utilizing comorbidity indices [ 36 ]. In our study, comorbidities were only associated with a higher probability of CML-specific death among men 60–69 years of age but not among older patients. Among the elderly males (> 70 years of age), other-cause deaths outweighed CML-specific deaths regardless of comorbidity. In contrast, among women with CML, comorbidity was only associated with a higher probability of CML-specific death in the oldest group (80+). Women with CML were more likely to die of CML-specific rather than other-cause death up to 89 years. Previous Swedish studies have noted a possible reluctance to treat elderly patients with tyrosine kinase inhibitors during the investigated time-period [ 39 , 46 ]. The present findings indicate that CML outcome could potentially be further improved among elderly, especially female patients.

Myeloma

Survival in multiple myeloma has increased during recent decades especially among younger patients (< 60-70 years), likely due to a combination of factors including increasing use of high-dose Melphalan with stem cell support and thalidomide as well as improvements in supportive care [ 47 , 48 ]. Previous studies have reported comorbidities to be of critical prognostic importance at myeloma diagnosis using different comorbidity indices [ 49 , 50 ]. In particular, renal impairment (pre-existing or disease-related) has been identified as an important determinant for myeloma outcome [ 50 , 51 ]. Kleber et al. have developed the Freiburg comorbidity index including performance status, renal impairment and lung disease, and have reported large differences in overall survival among 466 myeloma patients (median age 62 years) by the presence or absence of a combination of these factors [ 49 ]. In our study including ~ 4,500 myeloma patients with a median age of 72 years, we confirm the adverse prognostic impact of pre-existing renal and pulmonary disease, and extend the list of disorders associated with a higher risk of cancer-specific death to also include cardiovascular and cerebrovascular disease, dementia and psychiatric disorders. Hence, our study suggests that future evaluations of comorbidity and myeloma outcome in larger studies may benefit from including a broader list of disorders [ 52 ]. Interestingly, and in contrast with AML and CML, the prognostic impact of comorbid disease seemed relatively constant by age (among patients aged 60–89 years) [ 53 ].

The strengths of our study include the large size of the cohort, the high quality and coverage of the registers used as well as the population-based unselected setting, evaluating the effect of 12 severe comorbid diseases on outcome of hematological malignancies in the most recent decade. We also, for the first time in this setting, used a novel methodology to estimate probabilities of death associated with comorbidities in patients with hematological malignancies, in the presence of competing risks. While traditional ratio estimates of net survival (such as those presented in Table 2 ) are important to identify and evaluate the impact of prognostic factors associated with the disease under study, competing risks analyses may provide additional insights to understanding the real-world prognosis of the patients. This is because, in contrast to estimates of net survival, a competing risks analysis takes into account that causes other than the malignancy may kill the patient first and thereby preclude death from the malignancy. Thus, competing risks analyses more appropriately reflect the absolute impact of a prognostic factor on prognosis [ 54 ]. The advantage of studying the three different hematological malignancies together was to contrast between malignancy types needing intensive treatment upfront (AML) and those with slower tumor progression in need of more intermediate-intensity treatment (myeloma, CML). An important limitation of our study was the lack of clinical data such as performance status, disease-specific prognostic determinants including genetic abnormalities, and treatment. Since prior comorbidity may lead to lower performance status and may affect choices of treatment, rather than the other way around, performance status and treatment intensity may be considered explanatory factors rather than true confounders when estimating the impact of comorbidity on survival. Another limitation to consider is the definition of deaths as cancer-specific. Although the accuracy of the classification of main underlying cause of death has been found to be high for malignant diseases in the Swedish Cause-of-death registers [ 30 , 32 ], some leukemia/myeloma deaths may have been erroneously classified as non-cancer-related or vice versa. However, given that the majority of the deaths were cancer-specific and that we also present patterns of all-cause and other-cause deaths, a minor degree of such misclassification does not threaten our main conclusions.

Conclusion

Patients with AML, CML and myeloma have a high prevalence of comorbid disease especially in older ages. In the present study, comorbidities associated with worse cancer-specific mortality primarily included diseases associated with organ failure and with reduced cognitive function. Several comorbid diseases were associated with higher AML-specific and myeloma-specific mortality, whereas in CML, only renal disease was associated with a worse cancer-specific outcome. The impact of comorbidity varied by age and was most pronounced among AML patients younger than 70 years. Cancer-specific deaths outnumbered other-cause deaths in all patient groups except male patients with CML above 70 years of age. The results highlight the need for clinical awareness around comorbid patient groups and patient information, as well as an urgent need for the development and evaluation of alternative effective but less toxic treatment regimens.

Additional files

Additional file 1: Table S1. International Classification of Disease (ICD) codes, 10th revision, for classification of leukemia/myeloma, and comorbid diseases. (DOCX 13 kb) Additional file 2: Table S2. Number of outcome events and event rate overall and by type of comorbid disease. (DOCX 13 kb) Additional file 3: Table S3. Probabilities of death at 1, 2 and 5 years of follow-up among men aged 60–89 years. (DOCX 14 kb) Additional file 4: Table S4. Probabilities of death at 1, 2 and 5 years of follow-up among women aged 60–89 years. (DOCX 14 kb)

Competing interests

The authors report no potential conflicts of interest.

Authors’ contributions

KES was the principal investigator and takes primary responsibility for the paper; KES, MM and IG assembled the data; KES, MM, MB and SE are responsible for the study design; MM performed statistical analyses; YC, MB and SE participated in and supervised the statistical analysis; MM, IG, SE, and KES wrote the paper; YC and MB revised the manuscript; all authors approved of the final manuscript version.

Acknowledgements

The study was supported by a grant from the Stockholm County Council, grant no 20140204. Karin Ekström Smedby was further supported by the Strategic Research Program in Epidemiology at Karolinska Institutet. Ingrid Glimelius was supported from the Lion’s Fund. The funding agencies did not have any role in the study design, data collection, analyses, interpretation, manuscript writing or submission of this study.

References

1. Siegel R Ward E Brawley O Jemal A Cancer statistics, 2011 CA Cancer J Clin 2011 61 4 212 36 10.3322/caac.20121 21685461

2. GLOBOCAN 2012, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. [database on the Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available from: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx , accessed: on 12/06/2014.

3. Rose-Inman H Kuehl D Acute leukemia Emerg Med Clin North Am 2014 32 3 579 96 10.1016/j.emc.2014.04.004 25060251

4. Berglund A Garmo H Tishelman C Holmberg L Stattin P Lambe M Comorbidity, treatment and mortality: a population based cohort study of prostate cancer in PCBaSe Sweden J Urol 2011 185 3 833 9 10.1016/j.juro.2010.10.061 21239002

5. Jorgensen TL Hallas J Friis S Herrstedt J Comorbidity in elderly cancer patients in relation to overall and cancer-specific mortality Br J Cancer 2012 106 7 1353 60 10.1038/bjc.2012.46 22353805 PMC3314782

6. Land LH Dalton SO Jorgensen TL Ewertz M Comorbidity and survival after early breast cancer. A review Crit Rev Oncol Hematol 2012 81 2 196 205 10.1016/j.critrevonc.2011.03.001 21536452

7. Kobayashi Y Miura K Hojo A Hatta Y Tanaka T Kurita D Charlson comorbidity index is an independent prognostic factor among elderly patients with diffuse large B-cell lymphoma J Cancer Res Clin Oncol 2011 137 7 1079 84 10.1007/s00432-010-0973-x 21221637 PMC11828184

8. Plattel WJ Kluin-Nelemans HC de Bock GH van Imhoff GW Prognostic value of comorbidity for auto-SCT eligibility and outcome in relapsed or refractory aggressive non-Hodgkin’s lymphoma Bone Marrow Transplant 2011 46 6 827 34 10.1038/bmt.2010.188 20729926

9. Janssen-Heijnen ML van Spronsen DJ Lemmens VE Houterman S Verheij KD Coebergh JW A population-based study of severity of comorbidity among patients with non-Hodgkin’s lymphoma: prognostic impact independent of International Prognostic Index Br J Haematol 2005 129 5 597 606 10.1111/j.1365-2141.2005.05508.x 15916681

10. Xhaard A Porcher R Chien JW de Latour RP Robin M Ribaud P Impact of comorbidity indexes on non-relapse mortality Leukemia 2008 22 11 2062 9 10.1038/leu.2008.197 18685612 PMC2637383

11. Breccia M Frustaci AM Cannella L Stefanizzi C Latagliata R Cartoni C Comorbidities and FLT3-ITD abnormalities as independent prognostic indicators of survival in elderly acute myeloid leukaemia patients Hematol Oncol 2009 27 3 148 53 10.1002/hon.889 19274612

12. Djunic I Virijevic M Novkovic A Djurasinovic V Colovic N Vidovic A Comorbidity as a risk factor for overall survival and decision criteria for intensity of chemotherapy in elderly patients with acute myeloid leukemia Med Oncol 2012 29 2 1077 81 10.1007/s12032-011-9853-8 21331819

13. Etienne A Esterni B Charbonnier A Mozziconacci MJ Arnoulet C Coso D Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia Cancer 2007 109 7 1376 83 10.1002/cncr.22537 17326052

14. Ostgard LS Norgaard JM Sengelov H Severinsen M Friis LS Marcher CW Comorbidity and performance status in acute myeloid leukemia patients: a nation-wide population-based cohort study Leukemia 2014 29 3 548 55 10.1038/leu.2014.234 25092141

15. Farina L Bruno B Patriarca F Spina F Sorasio R Morelli M The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation Leukemia 2009 23 6 1131 8 10.1038/leu.2009.1 19194465

16. Raimondi R Tosetto A Oneto R Cavazzina R Rodeghiero F Bacigalupo A Validation of the hematopoietic cell transplantation-specific comorbidity index: a prospective, multicenter GITMO study Blood 2012 120 6 1327 33 10.1182/blood-2012-03-414573 22740454

17. Bokhari SW Watson L Nagra S Cook M Byrne JL Craddock C Role of HCT-comorbidity index, age and disease status at transplantation in predicting survival and non-relapse mortality in patients with myelodysplasia and leukemia undergoing reduced-intensity-conditioning hemopoeitic progenitor cell transplantation Bone Marrow Transplant 2012 47 4 528 34 10.1038/bmt.2011.138 21743502

18. Kristinsson SY Derolf AR Edgren G Dickman PW Bjorkholm M Socioeconomic differences in patient survival are increasing for acute myeloid leukemia and multiple myeloma in sweden J Clin Oncol 2009 27 12 2073 80 10.1200/JCO.2008.18.2006 19289627

19. Charlson ME Pompei P Ales KL MacKenzie CR A new method of classifying prognostic comorbidity in longitudinal studies: development and validation J Chronic Dis 1987 40 5 373 83 10.1016/0021-9681(87)90171-8 3558716

20. Quan H Sundararajan V Halfon P Fong A Burnand B Luthi JC Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data Med Care 2005 43 11 1130 9 10.1097/01.mlr.0000182534.19832.83 16224307

21. Barlow L Westergren K Holmberg L Talback M The completeness of the Swedish Cancer Register: a sample survey for year 1998 Acta Oncol 2009 48 1 27 33 10.1080/02841860802247664 18767000

22. Socialstyrelsen. The national board of health and welfare, Sweden. Available from: https://www.socialstyrelsen.se/register/halsodataregister/cancerregistret/inenglish . Accessed: 12/06/2014

23. Ludvigsson JF Andersson E Ekbom A Feychting M Kim JL Reuterwall C External review and validation of the Swedish national inpatient register BMC Public Health 2011 11 450 10.1186/1471-2458-11-450 21658213 PMC3142234

24. Abu-Shakra M Buskila D Ehrenfeld M Conrad K Shoenfeld Y Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies Ann Rheum Dis 2001 60 5 433 41 10.1136/ard.60.5.433 11302861 PMC1753641

25. Ravindran V Anoop P Rheumatologic manifestations of benign and malignant haematological disorders Clin Rheumatol 2011 30 9 1143 9 10.1007/s10067-011-1799-x 21698399

26. Knudsen LM Hippe E Hjorth M Holmberg E Westin J Renal function in newly diagnosed multiple myeloma--a demographic study of 1353 patients. The Nordic Myeloma Study Group Eur J Haematol 1994 53 4 207 12 10.1111/j.1600-0609.1994.tb00190.x 7957804

27. Statistics Sweden. Background Facts, Labour and Education Statistics 2009:1, Integrated database for labour market research. Statistics Sweden, Sweden 2009.

28. Winkleby MA Jatulis DE Frank E Fortmann SP Socioeconomic status and health: how education, income, and occupation contribute to risk factors for cardiovascular disease Am J Public Health 1992 82 6 816 20 10.2105/AJPH.82.6.816 1585961 PMC1694190

29. Liberatos P Link BG Kelsey JL The measurement of social class in epidemiology Epidemiol Rev 1988 10 87 121 3066632 10.1093/oxfordjournals.epirev.a036030

30. Johansson LA Westerling R Comparing Swedish hospital discharge records with death certificates: implications for mortality statistics Int J Epidemiol 2000 29 3 495 502 10.1093/ije/29.3.495 10869322

31. Howlader N Ries LA Mariotto AB Reichman ME Ruhl J Cronin KA Improved estimates of cancer-specific survival rates from population-based data J Natl Cancer Inst 2010 102 20 1584 98 10.1093/jnci/djq366 20937991 PMC2957430

32. Johansson LA Bjorkenstam C Westerling R Unexplained differences between hospital and mortality data indicated mistakes in death certification: an investigation of 1,094 deaths in Sweden during 1995 J Clin Epidemiol 2009 62 11 1202 9 10.1016/j.jclinepi.2009.01.010 19364635

33. Hinchliffe SR Lambert PC Flexible parametric modelling of cause-specific hazards to estimate cumulative incidence functions BMC Med Res Methodol 2013 13 13 10.1186/1471-2288-13-13 23384310 PMC3614517

34. Juliusson G Antunovic P Derolf A Lehmann S Mollgard L Stockelberg D Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry Blood 2009 113 18 4179 87 10.1182/blood-2008-07-172007 19008455

35. Appelbaum FR Gundacker H Head DR Slovak ML Willman CL Godwin JE Age and acute myeloid leukemia Blood 2006 107 9 3481 5 10.1182/blood-2005-09-3724 16455952 PMC1895766

36. Breccia M Luciano L Latagliata R Castagnetti F Ferrero D Cavazzini F Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival Leuk Res 2014 38 10 1173 6 10.1016/j.leukres.2014.06.020 25047978

37. Oran B Weisdorf DJ Survival for older patients with acute myeloid leukemia: a population-based study Haematologica 2012 97 12 1916 24 10.3324/haematol.2012.066100 22773600 PMC3590098

38. Budziszewska BK Pluta A Sulek K Wierzbowska A Robak T Giebel S Treatment of elderly patients with acute myeloid leukemia adjusted for performance status and presence of comorbidities; a Polish Adult Leukemia Group (PALG) study Leuk Lymphoma 2014 56 8 2331 8 10.3109/10428194.2014.985672 25393675

39. Bjorkholm M Ohm L Eloranta S Derolf A Hultcrantz M Sjoberg J Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008 J Clin Oncol 2011 29 18 2514 20 10.1200/JCO.2011.34.7146 21576640 PMC3138632

40. Hoglund M Sandin F Hellstrom K Bjoreman M Bjorkholm M Brune M Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry Blood 2013 122 7 1284 92 10.1182/blood-2013-04-495598 23843494 PMC3744993

41. Breccia M Molica M Colafigli G Zacheo I Latagliata R Tafuri A Correlation between Charlson comorbidity index and outcome in chronic phase chronic myeloid leukemia patients treated with second generation tkis upfront Leuk Lymphoma 2014 56 7 2206 7 10.3109/10428194.2014.993391 25549804

42. Iurlo A Ubertis A Artuso S Bucelli C Radice T Zappa M Comorbidities and polypharmacy impact on complete cytogenetic response in chronic myeloid leukaemia elderly patients Eur J Intern Med 2014 25 1 63 6 10.1016/j.ejim.2013.11.002 24309387

43. Marcolino MS Boersma E Clementino NC Macedo AV Marx-Neto AD Silva MH Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients Ann Oncol 2011 22 9 2073 9 10.1093/annonc/mdq715 21310760

44. Latagliata R Ferrero D Iurlo A Cavazzini F Castagnetti F Abruzzese E Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study Drugs Aging 2013 30 8 629 37 10.1007/s40266-013-0088-6 23681399

45. Breccia M Latagliata R Stagno F Luciano L Gozzini A Castagnetti F Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib Haematologica 2011 96 10 1457 61 10.3324/haematol.2011.041251 21685471 PMC3186306

46. Klepin HD, Rizzieri D, Palumbo A, Magarotto V, Eichhorst B. Individualizing treatment decisions for older adults with hematologic malignancies. American Society of Clinical Oncology educational book / ASCO American Society of Clinical Oncology Meeting. 2013:208–19. doi:10.1200/EdBook_AM.2013.33.208. 10.14694/EdBook_AM.2013.33.208 23714504

47. Kristinsson SY Landgren O Dickman PW Derolf AR Bjorkholm M Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003 J Clin Oncol 2007 25 15 1993 9 10.1200/JCO.2006.09.0100 17420512

48. Ludwig H Sonneveld P Davies F Blade J Boccadoro M Cavo M European perspective on multiple myeloma treatment strategies in 2014 Oncologist 2014 19 8 829 44 10.1634/theoncologist.2014-0042 25063227 PMC4122482

49. Kleber M Ihorst G Gross B Koch B Reinhardt H Wasch R Validation of the Freiburg Comorbidity Index in 466 multiple myeloma patients and combination with the international staging system are highly predictive for outcome Clin Lymphoma Myeloma Leuk 2013 13 5 541 51 10.1016/j.clml.2013.03.013 23810244

50. Kleber M Ihorst G Terhorst M Koch B Deschler B Wasch R Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM-comorbidity score Blood cancer J 2011 1 9 e35 10.1038/bcj.2011.34 22829196 PMC3255252

51. Eleutherakis-Papaiakovou V Bamias A Gika D Simeonidis A Pouli A Anagnostopoulos A Renal failure in multiple myeloma: incidence, correlations, and prognostic significance Leuk Lymphoma 2007 48 2 337 41 10.1080/10428190601126602 17325894

52. Sarfati D Gurney J Stanley J Salmond C Crampton P Dennett E Cancer-specific administrative data-based comorbidity indices provided valid alternative to Charlson and National Cancer Institute Indices J Clin Epidemiol 2014 67 5 586 95 10.1016/j.jclinepi.2013.11.012 24582212

53. Palumbo A, Gay F. How to treat elderly patients with multiple myeloma: combination of therapy or sequencing. Hematology / the Education Program of the American Society of Hematology American Society of Hematology Education Program. 2009:566–77. doi:10.1182/asheducation-2009.1.566. 10.1182/asheducation-2009.1.566 20008241

54. Eloranta S Adolfsson J Lambert PC Stattin P Akre O Andersson TM How can we make cancer survival statistics more useful for patients and clinicians: an illustration using localized prostate cancer in Sweden Cancer Causes Control 2013 24 3 505 15 10.1007/s10552-012-0141-5 23296456